Trending Bio Tech Stocks: ARIA, ARNA, AMGN, GILD, PPHM

Scottsdale, AZ -- (SBWIRE) -- 01/24/2013 -- Universal pennystocks.com focus is on Hot Penny Stocks that trade on OTCBB and OTC markets, which are mostly referred to as “penny stocks”. These Penny Stocks could offer the greatest potential return on your short or long term investment. Sign up for our free newsletter before you miss the next alert.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) was trading higher by -0.45 points or -2.27% to 19.40. So far, around 5.70 million shares have changed hands in this session. After opening at $19.50, the stock hit as high as $19.54. However, it traded between $13.92 and$25.40 over the last twelve months. ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients.

Why Should Investors Buy this stock After the Recent Fall? Just Go Here and Find Out

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) was at $8.72, showing a +0.46% increase. Around 3.94 million shares have been traded, versus an-average trading volume of 11.43 million shares. The company is now valued at around $1.89 billion. Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases.

Why Should Investors Buy this stock After The Recent Gain? Just Go Here and Find Out

Amgen, Inc. (NASDAQ:AMGN) moved -0.29 per cent lower at $82.83 and is trading between $82.12 and $83.92 after opening the day at $83.34. Its performance over the last five days remained -4.74%, which stands at -5.22% for a month. Going back further than one month, 1-year performance after recent close was +21.48%. Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada.

Will this stock Get Buyers Even After The Recent Rally? Find Out Here

Gilead Sciences, Inc. (NASDAQ:GILD)’s shares rose today, gaining +1.85 per cent to $78.26. The stock is up around +6.55% in 2013 and +64.17% for the last 12 months. Around 2.37 million shares changed hands so far in this session compared to an-average trading volume of 4.56 million shares. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases worldwide.

For How Long this stock will Fight for Profitability? Read This Trend Analysis report

The share price of Peregrine Pharmaceuticals (NASDAQ:PPHM) is ranging between $2.04 and $2.14. It was -2.36% lower at $2.07. During the past 52 weeks, the stock has ranged from a high of $5.50 to a low of $0.39. So far this year, shares have gained +56.83% and 1-year performance stands around +102.95%. Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, engages in the research and development of monoclonal antibodies for the treatment and diagnosis of cancer and viral infections.

Has this stock Found The Bottom And Ready To Gain Momentum? Find Out Here

About Universal Penny Stocks
universalpennystocks.com is an Independent Company, our focus is on small cap stocks that trade on OTCBB and OTC markets, and are mostly referred to as “penny stocks”. These are stocks that normally trade under $5 a share and could offer the greatest potential return on your short or long term investment. You must read our Disclaimer page for more information regarding conflicts of interest and the risks involved.

We try to spot stocks in all types of market conditions. In addition, we provide emerging small cap companies with profiling and investor relations services for compensation. If you believe your company is an emerging company, with a solid product, or a company that offers our members a profitable short or long term opportunity please feel free to send us an e-mail and we’ll review the company and reply to your inquiry promptly. Please provide as much information you believe we’ll need to review your request.